AETHLON MEDICAL INC (NASDAQ: AEMD) carries roughly 2.17 million shares of pending warrant supply against a tradeable float of approximately 512,630 shares — a ratio of almost five to one. That overhang earns the clinical-stage medical-device company a dilution risk score of 8 out of 10 (HIGH).
The float almost no one is quoting correctly
A 1-for-5 reverse split took effect July 31, 2026, compressing the outstanding share count to approximately 649,914. The split-adjusted float sits between 512,630 and 645,441 shares. Major data vendors have not yet processed the corporate action; their feeds still show a float north of 2.5 million — roughly five times the actual number. Any screen, chart overlay, or float-rotation calculation built on those stale figures will dramatically overstate how much stock is available to trade.
To put the real float in perspective: total pending warrant shares of roughly 2.53 million are about 3.9 times shares outstanding.
What is exercisable right now
The largest single structural feature is approximately 1,001,600 post-split pre-funded warrants — instruments that function like common stock except the holder pays a nominal exercise price, in this case half a penny ($0.005) per share. They are registered, require no stockholder vote, and can convert today. The only governor is a beneficial-ownership blocker — a contractual cap that prevents any single holder from exceeding 4.99% (or 9.99%) of shares outstanding at any moment. That blocker does not stop conversion; it merely paces it. The holder sells enough shares to create headroom, then exercises more warrants, creating a repeating supply loop.
The loop is already running. Between the July 7 offering closing and the July 23 measurement date — sixteen days — shares outstanding climbed 23%, from roughly 526,712 to 649,914 on a post-split basis. That increase can only be pre-funded warrant exercises.
What unlocks next
A second tranche of 1,126,602 common warrants struck at $3.55, plus 45,064 placement-agent warrants at the same strike, becomes exercisable the moment stockholders approve the offering terms. The company is contractually required to hold that vote no later than October 1, 2026. Every one of those underlying shares is already registered under an effective S-1 — meaning a resale registration, the SEC filing that lets shares trade freely on issuance — so they would enter the market with no further regulatory step.
Separately, a deeper-out-of-the-money tranche of roughly 391,498 warrants at a weighted-average strike of $32.40 appears inert. It is worth noting, however, that management repriced existing warrants down to $4.03 in a December 2025 inducement deal, setting a precedent for reactivating seemingly dead paper.
Structural guardrails and their limits
There are no convertible notes and no preferred stock in the capital structure. A one-year prohibition on variable-rate or price-reset securities — meaning instruments whose conversion price drops automatically as the stock falls — runs through July 7, 2027, which caps the classic death-spiral scenario.
But the company has completed five equity or equity-linked financings in eleven months, and a 90-day issuer lock-up from the July deal expires around October 5, 2026 — one business day after the stockholder-approval deadline. An ATM facility — a standing program that lets the company sell shares directly into the open market at prevailing prices — retains roughly $542,716 of capacity, constrained by a baby-shelf cap that limits how much a small issuer can sell under a simplified registration form.
The authorized share count stands at 20 million against 649,914 outstanding, leaving ample room for future issuance without a shareholder vote on new authorization. With quarterly cash burn of approximately $1.75 million and about $5 million on hand as of March 31, 2026, the structural incentive to tap that headroom within the next two to three quarters is arithmetically straightforward.